A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway.

Lichen BaoJun YinWen GaoQun WangWenbing YaoXiang-Dong Gao

Published in: British journal of pharmacology (2018)

Our data have uncovered some of the mechanisms by which PsTag600-FGF21 suppresses hepatic inflammation and further suggest that PsTag600-FGF21 could be an effective approach in NASH treatment.

Keyphrases

mouse model
oxidative stress
metabolic syndrome
signaling pathway
insulin resistance
type diabetes
electronic health record
big data
adipose tissue
liver injury
deep learning
combination therapy